Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.57 |
| ▸ | TACR1 | P25103 | 2/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | TDO2 | P48775 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.54 |
| ▸ | KYNU | Q16719 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL457686 | 1.00 | PPARA (0.57) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL295865 | 1.00 | PPARA (0.57) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL9572336 | 0.94 | CTSK (0.55) | PPARAPPARGCTSKTACR1CTSL | |
| SCHEMBL9572337 | 0.94 | CTSK (0.55) | PPARAPPARGCTSKTACR1CTSL | |
| Alanine SCHEMBL28766518 | 0.92 | CTSK (0.56) | PPARAPPARGCTSKCTSLCTSB | |
| SCHEMBL1192366 | 0.92 | PPARA (0.51) | PPARAPPARGCTSKTACR1CTRB1 | |
| SCHEMBL2677964 | 0.90 | CTSK (0.57) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL17446717 | 0.90 | CTSK (0.57) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL7032185 | 0.90 | CTSK (0.57) | CTSKTACR1CTRB1CTSLCTSB | |
| SCHEMBL13503284 | 0.89 | ALDH1A1 (0.64) | CTSKTACR1CTRB1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 787 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI NORMAL UNIVERSITY (CN) | 2023-08-03 | — | — | US | claimed |
| CN-113292430-B | Alpha-carbonyl alkenyl ester compound and preparation method and application thereof | 江西师范大学 | 2022-11-29 | — | — | CN | claimed |
| CN-114133398-B | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-11-22 | — | — | CN | claimed |
| CN-114133398-A | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-03-04 | — | — | CN | claimed |
| CN-108047268-B | 1-aza-5-gera-5-alkyl bicyclo [3.3.3] undecane compound, synthesis method and application | 中国科学技术大学 | 2020-05-01 | — | — | CN | claimed |
| CN-100494196-C | Indole alkaloid derivative, and its preparing method and use | UNIV CAPITAL MEDICAL (CN) | 2009-06-03 | — | — | CN | claimed |
| US-20060287500-A1 | Method for synthesis of C2-symmetric diamino diol mediated by titanium complexes | DEVELOPMENT CENTER FOR BIOTECHNOLOGY | 2006-12-21 | — | — | US | claimed |
| CN-1743327-A | Indole alkaloid derivative, and its preparing method and use | CAPITAL MEDICAL UNIV (CN) | 2006-03-08 | — | — | CN | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| EP-0396080-B1 | New serine derivatives, process for their preparation and their use in human therapy | FIDIA SPA (IT) | 1995-01-18 | — | — | EP | claimed |
| EP-0567207-A2 | Method of reducing impurities in aqueous monomer solutions | ROHM AND HAAS COMPANY (US) | 1993-10-27 | — | — | EP | claimed |
| US-5208370-A | Reducing protoanemonin by using phenylenediamines | ROHM AND HAAS CO. (US) | 1993-05-04 | — | — | US | claimed |
| EP-0016800-B1 | DETERMINATION OF PROTEOLYTIC ENZYMES IN BODY FLUIDS AND FLUOROGENIC SUBSTRATES | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1986-03-05 | — | — | EP | claimed |
| US-4336186-A | Analytical fluorogenic substrates for proteolytic enzymes | DADE INTERNATIONAL INC. | 1982-06-22 | — | — | US | claimed |
| US-4275153-A | Analytical fluorogenic substrates for proteolytic enzymes | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1981-06-23 | — | — | US | claimed |
| EP-0016800-A4 | Determination of proteolytic enzymes in body fluids and fluorogenic substrates. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1981-01-08 | — | — | EP | claimed |
| EP-0016800-A1 | Determination of proteolytic enzymes in body fluids and fluorogenic substrates. | AMERICAN HOSPITAL SUPPLY CORP (US) | 1980-10-15 | — | — | EP | claimed |
| WO-1980000351-A1 | ANALYTICAL FLUOROGENIC SUBSTRATES FOR PROTEOLYTIC ENZYMES | AMERICAN HOSPITAL SUPPLY CORP (US) | 1980-03-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ACSL1, ACSL4, WEE1 | PPARA 1057/4885PPARG 2298/4885CTSK 2595/4885 |
| US-20060287500-A1 | Method for synthesis of C2-symmetric diamino diol mediated by titanium complexes | TLL2, TLL1, CTSL | PPARA 3280/4885PPARG 4283/4885CTSK 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.